Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.

What was studied

This was a phase 2 study of abexinostat in follicular lymphoma. The lymphoma had come back or had not responded to earlier treatment. All patients had at least 2 earlier lines of treatment. The study had one arm and many centers. 90 patients were enrolled. They took abexinostat 80 mg by mouth on an on-and-off schedule. Cycles lasted 28 days. Treatment went on until harm or progression. The main goal was objective response rate.

What they found

Median follow-up was 30.55 months. 57 of 82 patients responded. 12 of 82 had a complete response. 75 of 82 had disease control. Tumors shrank in 73 of 82 patients. The median duration of response was 13.96 months. Median progression-free survival was 13.80 months. Median overall survival was 47.18 months. The most common side effects were low platelets, low neutrophils and low white cells. These affected 77, 53 and 47 of 90 patients.

What it means for patients

The authors say abexinostat showed efficacy and a manageable safety profile. They say the results support it as a new option for third-line or later treatment.

Why it is not certain yet

Only one group was treated. There was no comparison group. The response numbers cover 82 of the 90 patients. The abstract gives follow-up of 30.55 months. This is an early-stage trial.

Source

Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.

We restate facts from the source record in our own words. The original wording belongs to its publisher.